CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

TenecteplaseWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug2122 Placebo Wiki 0.05

Correlated MeSH Terms (0)

Name (Synonyms) Correlation

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Tenecteplase With Concomitant Anticoagulation for Severe Acute Respiratory Failure in Patients With COVID-19

This is a placebo-controlled, double blind, randomized, Phase II dose escalation study intended to evaluate the potential safety and efficacy of tenecteplase for the treatment of COVID-19 associated respiratory failure. The hypothesis is that administration of the drug, in conjunction with heparin anticoagulation, will improve patients' clinical outcomes.

NCT04505592 COVID-19 Respiratory Failure ARDS Drug: Tenecteplase Drug: Placebo
MeSH:Respiratory Insufficiency

Primary Outcomes

Description: The number of patients free of respiratory failure defined as not requiring high flow nasal cannula, non-rebreather, noninvasive positive pressure ventilation, or mechanical ventilation at 28 days

Measure: Number of participants free of respiratory failure

Time: 28 Days

Description: Safety as assessed by number of occurrences of intracranial bleeding or major bleeding

Measure: Number of occurrences of bleeding

Time: 28 days

Secondary Outcomes

Measure: Number of participants with in-hospital deaths at 14 days

Time: 14 days

Measure: Number of participants with death at 28 days

Time: 28 days

Measure: Number of ventilator-free days

Time: 28 days

Description: Respiratory failure-free defined as not requiring high flow nasal cannula, non-rebreather, noninvasive positive pressure ventilation, or mechanical ventilation

Measure: Number of respiratory failure-free days

Time: 28 days

Measure: Number of vasopressor-free days

Time: 28 days

Measure: Vasopressor doses at 24 hours

Time: 24 hours

Measure: Vasopressor doses at 72 hours

Time: 72 hours

Description: The P/F ratio equals the arterial pO2 ("P") from the ABG divided by the FIO2 ("F") - the fraction (percent) of inspired oxygen that the patient is receiving expressed as a decimal (40% oxygen = FIO2 of 0.40).

Measure: P/F ratio at 24 hours

Time: 24 hours

Description: The P/F ratio equals the arterial pO2 ("P") from the ABG divided by the FIO2 ("F") - the fraction (percent) of inspired oxygen that the patient is receiving expressed as a decimal (40% oxygen = FIO2 of 0.40).

Measure: P/F ratio at 72 hours

Time: 72 hours

Measure: Number of ICU-free days

Time: 28 days

Measure: Hospital length of stay

Time: 28 days

Measure: Number of participants with new-onset renal failure

Time: 28 days

Measure: Number of participants with need for renal replacement therapy

Time: 28 days

No related HPO nodes (Using clinical trials)